Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H23NO3PS |
Molecular Weight | 256.323 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CCOP(=O)(OCC)SCC[N+](C)(C)C
InChI
InChIKey=BJOLKYGKSZKIGU-UHFFFAOYSA-N
InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1
Echothiophate is a potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia. Echothiophate iodide for ophthalmic solution will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eye drop therapy by binding irreversibly to cholinesterase, and thus long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095233 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PHOSPHOLINE IODIDE Approved UseGlaucoma Chronic open-angle glaucoma. Subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated. Certain non-uveitic secondary types of glaucoma, especially glaucoma following cataract surgery. Accommodative Esotropia Concomitant esotropias with a significant accommodative component. Launch Date-3.00240011E11 |
|||
Palliative | PHOSPHOLINE IODIDE Approved UseGlaucoma Chronic open-angle glaucoma. Subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated. Certain non-uveitic secondary types of glaucoma, especially glaucoma following cataract surgery. Accommodative Esotropia Concomitant esotropias with a significant accommodative component. Launch Date-3.00240011E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Echothiophate iodide: its use in accommodative esotropia (high Ac/A ratio). | 1982 Jul |
|
Is succinylcholine appropriate or obsolete in the intensive care unit? | 2001 Oct |
|
Rapid activation of presynaptic nicotinic acetylcholine receptors by nerve-released transmitter. | 2003 Dec |
|
PI monovision for presbyopia. | 2004 |
|
H-7 effect on outflow facility after trabecular obstruction following long-term echothiophate treatment in monkeys. | 2004 Aug |
|
The effect of fluoride on the scavenging of organophosphates by human butyrylcholinesterase in buffer solutions and human plasma. | 2004 Jan 1 |
|
Screening assays for cholinesterases resistant to inhibition by organophosphorus toxicants. | 2004 Jun 1 |
|
Serine hydrolase targets of organophosphorus toxicants. | 2005 Dec 15 |
|
Mutant of Bungarus fasciatus acetylcholinesterase with low affinity and low hydrolase activity toward organophosphorus esters. | 2006 Sep |
|
Aging pathways for organophosphate-inhibited human butyrylcholinesterase, including novel pathways for isomalathion, resolved by mass spectrometry. | 2007 Nov |
|
Five tyrosines and two serines in human albumin are labeled by the organophosphorus agent FP-biotin. | 2008 Sep |
|
A phase II clinical trial to assess the safety of clonidine in acute organophosphorus pesticide poisoning. | 2009 Aug 20 |
|
Autonomic drugs and the accommodative system in rhesus monkeys. | 2010 Jan |
|
In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease. | 2010 Jun 16 |
|
Acute ocular complications from self-administered topical kermes. | 2010 Oct |
Patents
Sample Use Guides
Early Chronic Simple Glaucoma: echothiophate iodide for ophthalmic solution 0.03% instilled twice a day, just before retiring and in the morning, may be prescribed advantageously for cases of early chronic simple glaucoma that are not controlled around-the-clock with other less potent agents. Because of prolonged action, control during the night and early morning hours may then sometimes be obtained. A change in therapy is indicated if, at any time, the tension fails to remain at an acceptable level on this regimen.
Advanced Chronic Simple Glaucoma and Glaucoma Secondary to Cataract Surgery: these cases may respond satisfactorily to echothiophate iodide for ophthalmic solution 0.03% twice a day as above. When the patient is being transferred to echothiophate iodide for ophthalmic solution because of unsatisfactory control with pilocarpine, carbachol, epinephrine, etc., one of the higher strengths, 0.06%, 0.125%, or 0.25% will usually be needed. In this case, a brief trial with the 0.03% eyedrops will be advantageous in that the higher strengths will then be more easily tolerated.
Concomitant Therapy: echothiophate iodide for ophthalmic solution may be used concomitantly with epinephrine, a carbonic anhydrase inhibitor, or both. Technique – Good technique in the administration of echothiophate iodide for ophthalmic solution requires that finger pressure at the inner canthus should be exerted for a minute or two following instillation of the eyedrops, to minimize drainage into the nose and throat. Excess solution around the eye should be removed with tissue and any medication on the hands should be rinsed off.
Accommodative Esotropia (Pediatric Use) In Diagnosis: one drop of 0.125% may be instilled once a day in both eyes on retiring, for a period of two or three weeks. If the esotropia is accommodative, a favorable response will usually be noted which may begin within a few hours. In Treatment – Echothiophate iodide for ophthalmic solution is prescribed at the lowest concentration and frequency which gives satisfactory results. After the initial period of treatment for diagnostic purposes, the schedule may be reduced to 0.125% every other day or 0.06% every day. These dosages can often be gradually lowered as treatment progresses. The 0.03% strength has proven to be effective in some cases. The maximum usually recommended dosage is 0.125% once a day, although more intensive therapy has been used for short periods.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S01EB03
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
||
|
NCI_THESAURUS |
C47796
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
||
|
NDF-RT |
N0000000177
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
||
|
NDF-RT |
N0000007196
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
||
|
NDF-RT |
N0000175723
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
||
|
WHO-VATC |
QS01EB03
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4753
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
0F350BVT6S
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
SUB01856MIG
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
10548
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
Echothiophate
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
0F350BVT6S
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
89778
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | RxNorm | ||
|
C76040
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
100000087721
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
6736-03-4
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
Echothiophate
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
982
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY | |||
|
DB01057
Created by
admin on Fri Dec 15 15:49:16 UTC 2023 , Edited by admin on Fri Dec 15 15:49:16 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)